,30,38 Importantly, the current investigation extends these findings to suggest that CDK5 hyperactivation under glucotoxicity may contribute to the loss of beta cell function and insulin resistance, proposing CDK5 inhibitors as potential candidates for the treatment of T2D. The gene discussed is CDK5; the disease is Insulin resistance.